What is Saxenda?

Saxenda is the brand name for a once-daily injection of liraglutide 3 mg, made by Novo Nordisk. It's a GLP-1 receptor agonist, which is a long way of saying it's a lab-made version of a hormone your own gut releases after you eat. The FDA approved Saxenda for chronic weight management in December 2014, making it the first injectable GLP-1 officially indicated for obesity (not diabetes) in the United States.

If you've heard of Victoza, that's the same molecule — liraglutide — at a lower dose, sold for type 2 diabetes. Wegovy and Ozempic are newer GLP-1s based on semaglutide, a different (and longer-acting) molecule from the same manufacturer. Mounjaro and Zepbound are made by Eli Lilly and use tirzepatide, a dual GLP-1/GIP agonist. Saxenda is the original of the category; it's also now the oldest of the category.

How does Saxenda work for weight loss?

Saxenda works by imitating a natural hormone called glucagon-like peptide-1 (GLP-1). Your intestines release GLP-1 whenever you eat a meal, and it does three useful things: it signals your brain that you're full, it slows how fast your stomach empties so you stay full longer, and it tells your pancreas to release insulin appropriately. The problem is that your own natural GLP-1 breaks down within minutes. Saxenda is engineered to stick around for about half a day — long enough for one daily injection to keep those signals running.

When you're on Saxenda at the full 3.0 mg dose, most people describe three things happening, often without even noticing:

• Meals get smaller on their own. You sit down to eat, you're full after a few bites, and you don't feel the urge to clean your plate.
• Cravings go quiet. The "food noise" in your head — the background thinking about what to eat next — fades. Patients call this the most surprising part.
• You stay full longer. A normal lunch lasts until dinner instead of four hours.

None of this is willpower. That's the whole point of the drug: it's making a hormone adjustment that changes how hungry you feel, full stop. If it works for you, you lose weight because you eat less food, not because you're fighting harder.

Is Saxenda a GLP-1?

Yes. Saxenda is one of the original GLP-1 receptor agonists. It sits in the same drug class as Victoza, Ozempic, Wegovy, Trulicity, Bydureon, Rybelsus, Mounjaro, and Zepbound. They all target the GLP-1 receptor (Mounjaro and Zepbound also target GIP), but they differ in how long they last in your body, which brand they're sold under, and whether the FDA has approved them specifically for weight loss.

Who is Saxenda for?

The FDA label for Saxenda is specific. It's approved for adults with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related medical condition, such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. In 2020, the FDA extended the approval to include adolescents aged 12 to 17 with obesity.

Saxenda is meant as an adjunct to a reduced-calorie diet and increased physical activity. That language appears on every label of every GLP-1 weight-loss drug, and it matters: the drug is supposed to make the lifestyle changes possible, not replace them.

Who should not take Saxenda?

• Anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Anyone with a history of pancreatitis, or pancreatitis in the family.
• People who are pregnant, trying to become pregnant, or breastfeeding. All GLP-1s are contraindicated in pregnancy.
• People with severe gastroparesis (delayed gastric emptying), as Saxenda slows digestion further.
• Anyone with a serious allergic reaction to liraglutide or any component of the Saxenda pen.

Results you can expect on Saxenda

The pivotal data for Saxenda comes from the SCALE trial program, published in the New England Journal of Medicine in 2015. In the main SCALE Obesity and Prediabetes study, adults on Saxenda lost an average of 8% of their starting body weight over 56 weeks, compared to about 2.6% with placebo. Put in real numbers: a 220-pound adult on Saxenda for a year lost about 17–18 pounds, versus roughly 6 pounds with lifestyle changes alone.

Around 63% of Saxenda users lost 5% or more of their body weight, and about 33% lost 10% or more. Those aren't the numbers you see in Instagram testimonials — those are the trial averages, and they're the numbers you should plan around.

How long before Saxenda starts working?

Most people feel the appetite suppression within the first week, even at the 0.6 mg starter dose. Meaningful weight on the scale typically shows up between weeks 3 and 8, once you're past titration and at 2.4 or 3.0 mg. The FDA label recommends reassessing at 16 weeks: if you haven't lost at least 4% of your body weight by then, the evidence suggests Saxenda is unlikely to work for you, and switching or stopping makes sense.

What taking Saxenda actually looks like

A typical Saxenda experience looks like this:

• Week 1: 0.6 mg daily. One click on a fresh pen. Most people feel some nausea, maybe a little fatigue, and notice appetite changes by day 3–4.
• Week 2: 1.2 mg daily. Nausea may come back for a few days after the dose change, then fades.
• Week 3: 1.8 mg daily. Appetite suppression is usually very noticeable now.
• Week 4: 2.4 mg daily. This is often the toughest week for side effects.
• Week 5 and onward: 3.0 mg daily. Maintenance dose. All the published weight-loss data applies here.

You inject subcutaneously — into the fatty tissue of your abdomen, thigh, or upper arm — once a day, at any time you choose, with or without food. Most people pick a consistent time (morning or evening) and stick with it.

Risks and warnings

Saxenda carries a boxed warning — the strongest level of FDA warning — about the risk of thyroid C-cell tumors. The warning is based on animal studies in rodents; it has not been confirmed in humans, but the FDA still requires the boxed language. This is why anyone with a personal or family history of medullary thyroid carcinoma should not take Saxenda.

Beyond the thyroid warning, the most important safety concerns are:

• Pancreatitis. Severe abdominal pain that radiates to the back and doesn't go away is a reason to stop the drug and call your doctor immediately.
• Gallbladder problems. Saxenda can increase the risk of gallstones. Rapid weight loss in general raises this risk.
• Kidney problems. Severe nausea, vomiting, or diarrhea can cause dehydration, which can worsen kidney function — especially in people with existing kidney disease.
• Hypoglycemia. Not usually a concern for people without diabetes, but if you're on insulin or a sulfonylurea, Saxenda can push blood sugar too low.
• Suicidal thoughts. Reported in a small number of patients on weight-loss medications, including Saxenda. Any new mood changes should be raised with your prescriber.

The day-to-day side effects — nausea, constipation, fatigue, injection-site reactions — are covered in depth on our side effects page. They're common, usually manageable, and usually fade after the first month.

Saxenda vs newer GLP-1s

This is the part most people don't realize when they first research Saxenda. When Saxenda launched in 2014, it was the only FDA-approved injectable weight-loss drug in its class. That's no longer true. Since 2021, three newer GLP-1s have been approved or widely used for weight management, and the numbers they put up in trials are substantially better than Saxenda's:

• Wegovy (semaglutide) — same manufacturer as Saxenda, once-weekly injection, average weight loss of 14.9% in the STEP-1 trial.
• Ozempic (semaglutide) — technically a diabetes drug, widely used off-label for weight loss, weekly dosing, 12–15% typical weight loss.
• Zepbound (tirzepatide) — FDA-approved for weight loss in late 2023, weekly dosing, 20–22% average loss at the top dose in SURMOUNT-1.
• Mounjaro (tirzepatide) — same molecule as Zepbound, sold for diabetes, weekly dosing, often prescribed off-label for weight loss.

This is the central trade-off to understand. Saxenda is a proven, on-label, first-generation weight-loss GLP-1. The newer options offer roughly twice the weight loss with a once-a-week shot, and nearly all of them are now available through licensed telehealth services. For a lot of people, the honest recommendation in 2026 is to skip Saxenda entirely and start with one of the newer molecules — if you can access it.

When Saxenda is still a good pick

Saxenda still makes sense in a handful of specific situations:

• Your insurance covers Saxenda but not the newer drugs (rare in 2026 but still happens on older formularies).
• You want a shorter-acting drug in case you need to stop quickly — liraglutide washes out within a day or two.
• You've tried semaglutide or tirzepatide and had a bad reaction. Swapping to a different molecule in the same class can reset your tolerance.
• You're a teen in the 12–17 age range. Saxenda is the first GLP-1 FDA-approved for this group; newer drugs are following but slower to get pediatric labeling.

Common Saxenda questions

Quick facts recap

• Brand name: Saxenda (made by Novo Nordisk)
• Generic name: Liraglutide 3 mg
• Class: GLP-1 receptor agonist
• How it's taken: Subcutaneous injection, once daily, any time of day
• Maintenance dose: 3.0 mg per day
• Pens per month: 5 pens at the maintenance dose
• Typical retail cost: ~$1,349 per month without insurance
• Average weight loss: ~8% of body weight over a year (SCALE trial)
• Biggest risk: Thyroid C-cell tumors (boxed warning)
• Most common side effect: Nausea in the first few weeks